New trial tests which radiation combo best fights liver cancer

NCT ID NCT07293468

Recruiting now Disease control Sponsor: Tuen Mun Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This clinical trial compares two types of radiation therapy—SBRT and SIRT—each combined with immunotherapy, for people with advanced liver cancer that cannot be removed by surgery. About 106 participants will be randomly assigned to one of the two treatments. The goal is to see which approach provides longer control of the cancer with similar side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiation therapy (SBRT or SIRT) plus immunotherapy
What this could lead to: If successful, this could identify a more effective radiation approach to control advanced liver cancer when combined with immunotherapy, potentially extending life without progression.
What could go wrong: This is a mid-stage trial with only 106 participants, so results may not apply to all patients. Both treatments carry risks like liver damage or side effects from radiation and immunotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Tuen Mun Hospital
RECRUITING

Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.